{
  "id": 18222697,
  "title": "SK Biopharmaceuticals Q3 net income down 23.9% to $40.6 mil.",
  "url": "https://urgent.news/2026/11/05/sk-biopharmaceuticals-q3-net-income-down-23-9-to-40-6-mil-18222697",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-05T01:37:01.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times-koreatimes",
    "url": "https://www.koreatimes.co.kr/business/companies/20261105/sk-biopharmaceuticals-q3-net-income-down-239-to-406-mil"
  },
  "original_language": "en",
  "account": null,
  "summary": "SK Biopharmaceuticals (SK Biopharm), a biopharmaceutical arm of SK Group, on Thursday reported its third-quarter net income of 54.3 billion won ($40.6 million), down 23.9 percent from a year earlier. The biotech company said in a regulatory filing that operating profit for the July-September period rose 65.9 percent on-year to 116.3 billion won. Sales also increased 34.8 percent to 258.4 billion…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}